Search the Newsreel

Wall Street Zen Upgrades Editas Medicine (NASDAQ:EDIT) to Hold

Wall Street Zen has upgraded Editas Medicine (NASDAQ:EDIT) from "sell" to "hold." Despite this, broader analyst coverage remains "Moderate Buy" with a consensus price target of $5.40. The company recently surpassed quarterly earnings and revenue expectations, although company insiders have sold shares while institutional …

Editas Medicine director Ellinor Patrick Thomas II files initial beneficial ownership statement

Editas Medicine director Ellinor Patrick Thomas II has filed an initial beneficial ownership statement (Form 3) with the SEC, dated August 6. This filing indicates that Thomas is now a reporting owner for the company. The news brief was generated by Public Technologies (PUBT) …

Editas Medicine (NASDAQ: EDIT) grants director 103400 options at $2.9000

Editas Medicine (NASDAQ: EDIT) reported that director Ellinor Patrick Thomas II was granted 103,400 stock options with an exercise price of $2.9000 per share, expiring on August 5, 2036. These options vest in three equal annual installments starting August 6, 2027. Following this grant, …

Editas Medicine, Inc. (EDIT) director reports no share or option holdings

A director at Editas Medicine, Inc. (EDIT), Ellinor Patrick Thomas II, has filed an initial beneficial ownership report (Form 3) disclosing no holdings of common stock or derivative securities. The filing indicates no insider transaction activity, such as purchases or sales, associated with this …

Editas Medicine (EDIT) Stock Rallies On Revenue Jump But Losses Linger

Editas Medicine (EDIT) saw its stock rally by about 5% after reporting Q2 2026 earnings, driven by a significant increase in revenue to US$11.89 million from US$3.58 million year-on-year. While the company is still reporting losses, these narrowed to US$18.23 million from US$53.24 million, …

EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus

Editas Medicine (EDIT) reported a narrower-than-expected loss of 15 cents per share in Q2 2026, with revenues significantly surpassing estimates at $11.9 million due to deferred revenues. The company's lead gene-editing candidate, EDIT-401, for heterozygous familial hypercholesterolemia, showed encouraging preclinical data with rapid and …

Editas Medicine, Inc. 2026: Revenue $11.89M, EPS ($0.15) — 10-Q Summary

Editas Medicine, Inc. reported an increase in collaboration and research revenue to $11.89M for the quarter ended 2026, with a reduced net loss of ($18.23M) and improved diluted EPS of ($0.15). Key highlights include the nomination of EDIT-401 as the lead in vivo candidate …

Press Release: Editas Medicine Announces Second Quarter 2026 Results and Business Updates

Editas Medicine (NASDAQ: EDIT) announced its second quarter 2026 financial results and provided business updates. The company highlighted recent progress in its CRISPR-based therapeutic programs and discussed its financial position, offering insights into its strategic direction and upcoming milestones for the remainder of the …

Editas Medicine (NASDAQ:EDIT) Issues Earnings Results

Editas Medicine (NASDAQ:EDIT) announced its quarterly earnings, reporting an adjusted loss of $0.15 per share, surpassing the consensus estimate of a $0.27 loss, with revenue of $11.89 million, significantly exceeding analyst expectations of $2.85 million. Despite beating revenue and EPS estimates, the company remains …

Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates

Editas Medicine (EDIT) reported a Q2 loss of $0.15 per share, surpassing the Zacks Consensus Estimate of a $0.3 loss and representing a 50% surprise. The company also beat revenue estimates with $11.89 million, significantly higher than the $3.58 million from the previous year. …

Editas Medicine (EDIT) CFO tax-related share sale executed under preset plan

Editas Medicine's CFO, Amy Parison, sold 678 shares of common stock at $2.58 per share on August 3, 2026. This transaction was executed under a pre-established Rule 10b5-1 plan to cover tax withholding obligations from restricted stock units that vested on August 1, 2026, …

Editas Medicine (Nasdaq: EDIT) equity deal lifts cash to $211.6M

Editas Medicine reported a Q2 2026 net loss of $18.2 million, significantly trimmed from $53.2 million a year prior, and saw collaboration revenues increase to $11.9 million. The company's cash, cash equivalents, and marketable securities totaled $211.6 million as of June 30, 2026, boosted …

Editas Medicine (EDIT) Earnings Date and Reports 2026 $EDIT

Editas Medicine earnings beat by $0.12, revenue topped estimates

Editas Medicine (EDIT) Projected to Post Quarterly Earnings on Tuesday

Editas Medicine (EDIT) is expected to announce its Q2 2026 earnings before market open on Tuesday, August 11th, with analysts forecasting a loss of $0.30 per share and $2.85 million in revenue. The company's previous quarter showed a narrower-than-expected loss but significantly missed revenue …

A cardiovascular leader joins Editas as a director steps down

Editas Medicine has appointed Dr. Patrick T. Ellinor, a renowned leader in cardiovascular medicine and human genetics, to its Board of Directors, effective August 6, 2026. Dr. Ellinor's expertise is expected to significantly contribute to the advancement of EDIT-401 for hyperlipidemia and the company's …

Editas Medicine appoints Patrick Ellinor to board of directors

Editas Medicine has appointed Patrick T. Ellinor, M.D., Ph.D., to its Board of Directors, effective August 6. Dr. Ellinor brings extensive experience in human genetics and cardiovascular research from his roles at Mass General Brigham Heart and Vascular Institute and the Broad Institute. He …

Renaissance Technologies LLC Raises Position in Editas Medicine, Inc. $EDIT

Renaissance Technologies LLC increased its stake in Editas Medicine, Inc. by 30.7% in the first quarter of 2026, acquiring an additional 932,382 shares to own a total of 3.97 million shares valued at $9.8 million. Other institutional investors also adjusted their holdings, with hedge …

Editas Medicine EVP, chief scientific officer, sells $13,157 in stock By Investing.com

Linda Burkly, EVP and Chief Scientific Officer of Editas Medicine (NASDAQ:EDIT), sold 4,928 shares totaling approximately $13,157 to cover tax obligations from vested restricted stock units. This non-discretionary sale occurred as the stock saw a 31% gain over six months, despite its high volatility. …

Editas Medicine (NASDAQ:EDIT) EVP Linda Burkly Sells 4,928 Shares of Stock

Editas Medicine EVP Linda Burkly sold 4,928 shares of the company's stock for approximately $13,158, reducing her holdings by 7.32%. The sale was part of a pre-arranged plan to cover tax obligations related to vested equity awards. The company recently reported better-than-estimated earnings per …

Editas Medicine Inc (EDIT) Income Statement

This article provides the quarterly and annual income statement for Editas Medicine Inc (EDIT), allowing users to analyze its financial performance and operational efficiency. It presents data including total revenue, operating expenses, net income, and earnings per share across various fiscal quarters and years. …

Editas Medicine, Inc. Revenue Breakdown – NASDAQ:EDIT

Editas Medicine, Inc. (NASDAQ: EDIT) generated $40.52 million USD in revenue last year, primarily from its Gene Editing Technology segment, an increase from $32.31 million USD the prior year. All of this revenue was attributed to the United States market. The article provides a …

EDIT|Editas Medicine Inc|Price:2.600|Chg%:-0.130

Editas Medicine Inc. (EDIT) has healthy fundamentals and significant growth potential, although its stock price is expected to trend down in the medium term. The company is currently fairly valued within the Biotechnology & Medical Research industry and shows very high institutional ownership. Analysts …

Editas Medicine Inc (EDIT) Valuation: PE, PB & Fair Value Analysis

Editas Medicine Inc (EDIT) has a current valuation score of 7.00, placing it 277th out of 386 companies in the Biotechnology & Medical Research industry. The article highlights the company's P/E ratio of -2.28, which is significantly below its recent high and above its …

Form 144 Editas Medicine For: 22 July By Investing.com

This article from Investing.com is a brief announcement regarding the filing of Form 144 for Editas Medicine on July 22. It provides a quick update on a regulatory filing for the biotech company. The article contains minimal content beyond the title, indicating it's likely …

Editas Medicine stock trades steady as gene-editing pipeline advances and cash runway extends

Editas Medicine (EDIT) is balancing its cash usage with clinical pipeline advancements in gene-editing. The company's recent quarterly figures for fiscal 2025 showed approximately $9 million in revenue from collaborations, a substantial net loss reflecting high R&D costs, and a cash position of about …

Editas Medicine, Inc. (NASDAQ:EDIT) Given Average Rating of "Moderate Buy" by Analysts

Editas Medicine, Inc. (NASDAQ:EDIT) has received a consensus "Moderate Buy" rating from analysts, with an average target price of $5.40. The company recently reported better-than-expected EPS but missed revenue estimates, and its CEO sold a significant number of shares. Institutional investors hold approximately 71.9% …

Editas Medicine (EDIT) insider plans to sell 5,500 shares after RSU vesting

Linda C. Burkly, an insider at Editas Medicine (EDIT), has filed a Form 144 indicating an intention to sell up to 5,500 shares of common stock on or after July 27, 2026. These shares are associated with Restricted Stock Unit vesting, with 11,292 shares …

Editas Medicine stock steadies as gene-editing pipeline advances after Q1 loss narrows

Editas Medicine (EDIT) saw its stock steady after reporting a narrowed Q1 2024 net loss of $34.3 million, down from $36.3 million year-over-year. The company's revenue declined to $5.4 million from $6.6 million, primarily due to lower collaboration income, but disciplined spending and a …

Editas Medicine (NASDAQ:EDIT) Share Price Passes Below Fifty Day Moving Average - What's Next?

Editas Medicine (NASDAQ:EDIT) shares recently fell below their 50-day moving average, closing at $2.88, which indicates short-term technical weakness. Analyst sentiment is mixed but leans towards "Moderate Buy" with a consensus price target of $5.40, despite recent downgrades and challenging fundamentals like missed revenue …